New technology promises to eliminate airborne COVID virus
Air decontamination technology developed by Biomoneta, a Bengaluru-based start-up backed by the Indian and Karnataka governments, promises to remove airborne COVID-19 virus with a 99.9999% efficiency in any confined setting. The Department of Biotechnology's Biotechnology Industry Research Assistance Council helped the company undertake validation studies at the Indian Institute of Science in Bengaluru (DBT-BIRAC).
C-COVID-19 CIDA's Innovations Deployment Accelerator programme (C-CIDA) developed the technology, which is pathogen indifferent. In prior ICMR/NABL-accredited lab trials, it has also eliminated airborne microorganisms with 99.999 percent effectiveness.
It's also shown efficient against pathogens including Mycobacterium TB, Candida, and influenza viruses like H1N1, which are infamous for causing secondary infections in hospitals.
Due to the fact that TB is still a neglected disease without a preventive vaccination, its efficacy against the TB pathogen, Mycobacterium tuberculosis, is particularly essential. Because it is airborne, the virus that causes the disease is extremely contagious and can spread through strains that are resistant to currently available antibiotics.
Following COVID, Biomoneta's co-founder and CEO, Janani Venkatraman, highlighted that air purification requires microbe-specific requirements. "Even in cutting-edge medical facilities, approaches for disinfecting the air depend on particulate matter removal as a substitute for microbiological decontamination. Our medical and surgical methods have progressed tremendously throughout the years. We want air sterilisation to be on the same level as hand sterilisation."
CTO and co-founder Arindam Ghatak stated, "Lab data is important, but the real impact is determined by how the technology transfers to the end user. This has been demonstrated in collaboration with hospitals, clinics, IVF labs, offices and cafeterias."
For C-CAMP incubated startup Biomoneta CEO and Director Dr Taslimarif Saiyed, the company is proof of what deep-science-led innovations can achieve to solve a critical challenge for COVID and, going beyond COVID, for non-COVID airborne diseases.